Search results for " Questionnaires"

showing 10 items of 2407 documents

Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology.

2015

Aim To assess patient perception toward oral chemotherapy for solid tumors, the Italian Association of Medical Oncology performed a large multi-institutional national survey. Methods A 17-item anonymous questionnaire including 7 general and 10 investigational questions with free-text, single-choice, or multiple-choice answers was administered. Analysis of response distribution according to predefined factors was described by summary measures and conducted by χ2 test and other nonparametric tests. Results From January to June 2010, 581 patients completed the questionnaire; data of 404 patients constituted the final study sample. Three groups could be distinguished according to treatment: IV …

OncologyAdultMaleCancer Researchmedicine.medical_specialtyOral chemotherapyAdministration OralWork commitment03 medical and health sciences0302 clinical medicineInternal medicineNeoplasmsSurveys and QuestionnairesAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansImpact on family030212 general & internal medicineInfusions IntravenousOral therapyAgedbusiness.industryIntravenous chemotherapyGeneral MedicineMiddle AgedPatient perceptionsOncologyItaly030220 oncology & carcinogenesisQuality of LifeCombined therapyFemalebusinessTumori
researchProduct

The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicent…

2016

Elderly breast cancer patients are affected by poorer quality of life (QoL) compared to younger patients. Because QoL has a relevant impact on guideline-adherent treatment, elderly breast cancer patients are often undertreated, especially with regard to adjuvant chemotherapy, and overall survival is decreased. Thus, understanding the impact of chemotherapy on QoL in elderly patients is crucial. This study compared QoL in patients aged 65 years and 65 to 70 years receiving adjuvant chemotherapy as a secondary outcome in the prospective randomized multicenter ADEBAR trial.Patients with lymph node-positive breast cancer were prospectively randomized for either sequential anthracycline-taxane o…

OncologyCancer ResearchDocetaxel0302 clinical medicineQuality of lifeSurveys and QuestionnairesAntineoplastic Combined Chemotherapy ProtocolsMulticenter Studies as TopicAnthracyclinesLongitudinal StudiesProspective Studies030212 general & internal medicineYoung adultProspective cohort studyAntibiotics AntineoplasticAge FactorsMiddle AgedhumanitiesOncologyDocetaxelChemotherapy Adjuvant030220 oncology & carcinogenesisPractice Guidelines as TopicFemaleTaxoidsFluorouracilmedicine.drugEpirubicinAdultBridged-Ring Compoundsmedicine.medical_specialtyAdolescentCyclophosphamideBreast NeoplasmsYoung Adult03 medical and health sciencesBreast cancerInternal medicinemedicineHumansCyclophosphamideAgedEpirubicinbusiness.industryCancermedicine.diseaseClinical Trials Phase III as TopicQuality of LifePatient CompliancebusinessClinical Breast Cancer
researchProduct

Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists

2010

Abstract Background Overall survival (OS) is the gold standard for the demonstration of a clinical benefit in cancer trials. Replacement of OS by a surrogate endpoint allows to reduce trial duration. To date, few surrogate endpoints have been validated in digestive oncology. The aim of this study was to draw up an ordered list of potential surrogate endpoints for OS in digestive cancer trials, by way of a survey among clinicians and methodologists. Secondary objective was to obtain their opinion on surrogacy and quality of life (QoL). Methods In 2007 and 2008, self administered sequential questionnaires were sent to a panel of French clinicians and methodologists involved in the conduct of …

OncologyCancer ResearchTime FactorsDigestive System Neoplasms[ SDV.CAN ] Life Sciences [q-bio]/Cancer0302 clinical medicineQuality of lifeSurveys and QuestionnairesMedicine030212 general & internal medicineMESH: Treatment OutcomeResponse rate (survey)MESH : Evidence-Based MedicineClinical Trials as TopicEvidence-Based MedicineMESH: Endpoint DeterminationMESH: Research DesignMESH : QuestionnairesMESH : Research Designlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthMESH: Reproducibility of Resultsmedicine.anatomical_structureTreatment OutcomeOncologyResearch Design030220 oncology & carcinogenesisData Interpretation StatisticalMESH: Survival AnalysisMESH : Disease-Free SurvivalMESH : Endpoint DeterminationFranceMESH : Time FactorsResearch Articlemedicine.medical_specialtyMESH: Clinical Trials as TopicEndpoint DeterminationRectum[SDV.CAN]Life Sciences [q-bio]/CancerMESH : Treatment Outcomelcsh:RC254-282Disease-Free Survival03 medical and health sciences[SDV.CAN] Life Sciences [q-bio]/CancerInternal medicineGeneticsHumansMESH : Data Interpretation StatisticalMESH : FranceSurvival analysisMESH: Humansbusiness.industrySurrogate endpointMESH: Digestive System NeoplasmsMESH : Reproducibility of ResultsMESH: QuestionnairesMESH : HumansMESH: Time FactorsCancerReproducibility of ResultsMESH: Quality of LifeMESH : Quality of Lifemedicine.diseaseSurvival AnalysisMESH : Clinical Trials as TopicMESH: FranceLocalized diseaseEndpoint DeterminationMESH: Disease-Free SurvivalQuality of LifeMESH : Digestive System NeoplasmsMESH : Survival AnalysisbusinessMESH: Data Interpretation StatisticalMESH: Evidence-Based MedicineBMC Cancer
researchProduct

Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow‐Up Survey

2020

Abstract Background Fundamental Research in Oncology and Thrombosis (FRONTLINE) is a global survey of physicians' perceptions and practice in the management of venous thromboembolism (VTE) in patients with cancer. Materials and Methods The present survey, FRONTLINE 2, follows the original FRONTLINE survey (published in The Oncologist in 2003) and provides insights into how physicians perceive risk of VTE in cancer and approach its prophylaxis and treatment. Results Between November 2015 and February 2016, 5,233 respondents participated, representing cancer physicians and surgeons. Most believed that less than one in five patients with any cancer might be at risk of VTE, with a slightly high…

OncologyCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatment26030204 cardiovascular system & hematologyFondaparinuxDabigatranVenous thromboembolism • Cancer-associated thrombosis • Deep vein thrombosis • Pulmonary embolism • Central venous catheter.03 medical and health sciences0302 clinical medicineInternal medicineSurveys and QuestionnairesVenous thromboembolism • Cancer‐associated thrombosis • Deep vein thrombosis • Pulmonary embolism • Central venous cathetermedicineHumansRivaroxabanbusiness.industryAnticoagulantWarfarinCancerAnticoagulantsThrombosisVenous ThromboembolismHeparin Low-Molecular-Weightmedicine.diseasePulmonary embolismOncologySymptom Management and Supportive Care030220 oncology & carcinogenesisbusinessCentral venous cathetermedicine.drugFollow-Up StudiesThe Oncologist
researchProduct

Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Adva…

2012

INTRODUCTION:: The TORCH (Tarceva or Chemotherapy) trial randomized patients with advanced non-small-cell lung cancer to first-line erlotinib followed by second-line cisplatin/gemcitabine versus. standard inverse sequence. The trial, designed to test noninferiority in overall survival, was stopped at interim analysis because of inferior survival in the experimental arm. Quality of life (QoL), a secondary outcome, is reported here. METHODS:: QoL was assessed at baseline and every 3 weeks during first-line, using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 and QLQ-lung cancer specific module (LC13). Mean changes from baseline within arms …

OncologyMaleerlotinibLung NeoplasmsHealth-related quality of lifeNSCLCchemotherapyDeoxycytidinelaw.inventionRandomized controlled trialQuality of lifelawCarcinoma Non-Small-Cell LungSurveys and QuestionnairesAntineoplastic Combined Chemotherapy ProtocolsSurveys and QuestionnaireQuality of life analysis of TORCHErlotinib HydrochloridePrognosishumanitiesOncologyResearch DesignAdvanced non–small-cell lung cancerCarcinoma Squamous CellFemaleErlotinibRandomized trialmedicine.drugHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyPrognosiEGFRFirst-line treatmentfirst-line erlotinibsecond-line cisplatin/gemcitabine chemotherapyAdenocarcinomaNOFollow-Up StudieErlotinib HydrochlorideInternal medicineadvanced non-small-cell lung cancermedicineHumansLung cancerAdvanced non-small-cell lung cancer; Chemotherapy; EGFR; Erlotinib; First-line treatment; Health-related quality of life; Randomized trialQuality of life analysis of TORCH first-line erlotinib second-line cisplatin/gemcitabine chemotherapy advanced non-small-cell lung cancer.AgedNeoplasm StagingSalvage TherapyAntineoplastic Combined Chemotherapy Protocolbusiness.industryQuestionnaireCancerQuinazolinemedicine.diseaseInterim analysisGemcitabineGemcitabineSurgeryLung Neoplasmquality of lifeQuinazolinesCarcinoma Large CellCisplatinNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions

2013

The validated EndoPredict assay is a novel tool to predict the risk of metastases of patients with estrogen receptor positive, HER2 negative breast cancer treated with endocrine therapy alone. It has been designed to integrate genomic and clinical information and includes clinico-pathological factors such as tumor size and nodal status. The test is feasible in a decentral setting in molecular pathology laboratories. In this project, we investigated the performance of this test in clinical practice, and performed a retrospective evaluation of its impact on treatment decisions in breast cancer. During one year, EndoPredict assays from 167 patients could be successfully performed. For retrospe…

OncologyNon-Clinical Medicinemedicine.medical_treatmentCancer Treatmentlcsh:MedicineEstrogen receptorBioinformaticsMetastasisSurveys and QuestionnairesPathologylcsh:ScienceMultidisciplinaryMolecular pathologyCancer Risk FactorsHormonal TherapyObstetrics and GynecologyEndocrine TherapyMiddle AgedOncologyReceptors EstrogenCohortMedicineFemaleRisk assessmentMolecular PathologyResearch ArticleAdultmedicine.medical_specialtyAntineoplastic Agents HormonalGenetic Causes of CancerClinical Decision-MakingBreast NeoplasmsRisk AssessmentBreast cancerDiagnostic MedicineInternal medicineBreast CancermedicineHumansAgedRetrospective StudiesChemotherapyHealth Care Policybusiness.industryGene Expression Profilinglcsh:RHealth Risk AnalysisRetrospective cohort studyChemotherapy and Drug Treatmentmedicine.diseaselcsh:QbusinessGeneral PathologyPLoS ONE
researchProduct

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

2015

Abstract Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) are hematologically diverse stem cell malignancies sharing phenotypic features of both myelodysplastic syndromes and myeloproliferative neoplasms. There are currently no standard treatment recommendations for most adult patients with MDS/MPN. To optimize efforts to improve the management and disease outcomes, it is essential to identify meaningful clinical and biologic end points and standardized response criteria for clinical trials. The dual dysplastic and proliferative features in these stem cell malignancies define their uniqueness and challenges. We propose response assessment guidelines to harmonize future…

Oncologymedicine.medical_specialtyInternational CooperationImmunologyMEDLINEMedical OncologyBiochemistryMyeloproliferative DisordersSurveys and QuestionnairesInternal medicinehemic and lymphatic diseasesmedicineHumansResponse criteriaCell ProliferationClinical Trials as TopicMyeloproliferative DisordersAdult patientsSurrogate endpointbusiness.industryStandard treatmentMyelodysplastic syndromesfood and beveragesCell BiologyHematologymedicine.diseaseClinical trialPhenotypeTreatment OutcomeHematologic NeoplasmsMyelodysplastic SyndromesMutationPractice Guidelines as TopicDisease ProgressionPhysical therapybusinessAlgorithmsPerspectives
researchProduct

S-Adenosylmethionine Supplementation May Reduce Cancer-Related Fatigue: A Prospective Evaluation Using the FACIT-F Questionnaire in Colon Cancer Pati…

2021

<b><i>Background:</i></b> Fatigue is a common distressing symptom for patients living with chronic or acute diseases, including liver disorders and cancer (<i>Cancer-Related Fatigue</i>, CRF). Its etiology is multifactorial, and some hypotheses regarding the pathogenesis are summarized, with possible shared mechanisms both in cancer and in chronic liver diseases. A deal of work has investigated the role of a multifunctional molecule in improving symptoms and outcomes in different liver dysfunctions and associated symptoms, including chronic fatigue: S-adenosylmethionine (SAM; AdoMet). The aim of this work is actually to consider its role also in oncologic…

Oncologymedicine.medical_specialtyS-AdenosylmethionineBevacizumabCancer-related fatigueColorectal cancerAdoMetFOLFOXInternal medicineSurveys and QuestionnairesDrug DiscoverymedicineHumansPharmacology (medical)Cancer-related fatigueFatiguePharmacologybusiness.industryCancerChronic fatigueGeneral Medicinemedicine.diseaseCancer treatment toxicityOxaliplatinColon cancerOxaliplatinRegimenInfectious DiseasesOncologyFunctional Assessment of Chronic Illnesses Therapy-FatigueColonic NeoplasmsDietary SupplementsQuality of Lifemedicine.symptombusinessmedicine.drugChemotherapy
researchProduct

Oral health-related quality of life after dental treatment in patients with intellectual disability

2020

Background The influence of dental treatment on oral health-related quality of life (OHRQOL) has rarely been evaluated in patients with intellectual disability (ID) through validated questionnaires. The aim of this study was to estimate the changes on OHRQOL in patients with ID after the implementation of an institutional dental treatment program under general anesthesia using the Franciscan Hospital for Children Oral Health-Related Quality of Life questionnaire (FHCOHRQOL-Q). Material and Methods A prospective longitudinal study was conducted on 85 patients (mean age=24.85 years) classified according to DSM-V whose parents/caregivers completed the FHC-OHRQOL-Q. We analyzed the changes in t…

Oral health-related quality of lifeLongitudinal studyGeneral anesthesiaDentistryOral HealthDental CariesOral health03 medical and health sciences0302 clinical medicineQuality of lifeIntellectual DisabilitySurveys and QuestionnairesIntellectual disabilityHumansMedicineIn patientLongitudinal StudiesProspective StudiesChildProspective cohort studySpecial needsGeneral Dentistrybusiness.industryResearchDMFT Index030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Medically compromised patients in Dentistrymedicine.diseasestomatognathic diseasesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASDental treatmentQuality of LifeSurgeryMultiple linear regression analysisFranciscan Hospital for Children Oral Health-Related Quality of Life questionnairebusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Assessment of sleep disturbance in oral lichen planus and validation of PSQI: A case-control multicenter study from the SIPMO (Italian Society of Ora…

2021

Background: The wellbeing of oral lichen planus patients (OLPs) may be strongly influenced by a poor quality of sleep (QoS) and psychological impairment. The aims were to analyze the prevalence of sleep disturbance, anxiety, and depression in OLPs and to validate the Pittsburgh Sleep Quality Index (PSQI) in OLPs. Methods: Three hundred keratotic OLPs (K-OLPs), 300 with predominant non-keratotic OLP (nK-OLPs), and 300 controls were recruited in 15 Italian universities. The PSQI, Epworth Sleepiness Scale (ESS), Hamilton Rating Scales for Depression and Anxiety (HAM-D and HAM-A), Numeric Rating Scale (NRS), and Total Pain Rating Index (T-PRI) were administered. Results: Oral lichen planus pati…

OralSleep Wake DisordersCancer Researchmedicine.medical_specialtyanxiety; insomnia; mood disturbance; oral lichen planus; sleep disturbance; Anxiety; Case-Control Studies; Depression; Female; Humans; Pathology Oral; Reproducibility of Results; Sleep; Surveys and Questionnaires; Lichen Planus Oral; Sleep Wake DisordersinsomniaReproducibility of Resultoral lichen planuPathology and Forensic MedicineSettore MED/28 - MALATTIE ODONTOSTOMATOLOGICHEPittsburgh Sleep Quality Indexoral lichen planusstomatognathic systemSurveys and QuestionnairesInsomniamedicineNumeric Rating ScalePathologySurveys and QuestionnaireHumansanxiety; insomnia; mood disturbance; oral lichen planus; sleep disturbancemood disturbanceSleep disorderbusiness.industryDepressionEpworth Sleepiness ScaleLichen PlanusReproducibility of ResultsRating scales for depressionmedicine.diseaseanxietysleep disturbancehumanitiesstomatognathic diseasesOtorhinolaryngologyCase-Control StudiesPathology OralPhysical therapyPeriodonticsAnxietyOral lichen planusFemaleOral Surgerymedicine.symptomCase-Control StudiebusinessSleepHumanLichen Planus Oral
researchProduct